HSBC raised the firm’s price target on Regeneron (REGN) to $985 from $890 and keeps a Buy rating on the shares as part of a ...

(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending ...

Regeneron Pharmaceuticals (REGN) shares have shown steady gains over the past month, supported by the company’s consistent revenue and net income growth. Investors are keeping an eye on how Regeneron ...

Feb 4 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a ...

The U.S. Department of Justice filed a lawsuit accusing Regeneron Pharmaceuticals of manipulating Medicare pricing by inflating the average sales price for its expensive and widely prescribed Eylea ...

(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending ...

It's full steam ahead for a new Regeneron facility in Saratoga Springs. The company has learned that Saratoga County's ...

On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the consensus of $11.29. The company reported sales of $3.79 ...

Dec 16 - Regeneron Pharmaceuticals (REGN.O), opens new tab has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV, according to filings in New York federal ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...